Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Weill Cornell Medicine

Sites in New York, NY

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 6:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
779
Shown on this page
12
Current sort
Recently updated
Campus scope
Weill Cornell Medicine, New York, NY
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Weill Cornell Medicine, New York, NY. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 373–384 of 779 matching trials with a site at Weill Cornell Medicine, New York, NY.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)

NCT06101329
Site status not listed — check the official record
View directory record Official record
Conditions
Pre-Exposure Prophylaxis of HIV Infection
Interventions
Lenacapavir Tablet, Lenacapavir Injection, Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older · Female only
Enrollment
253 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
11
States / cities
Birmingham, Alabama • San Diego, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 22, 2026, 6:45 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Center for Research and Education on Aging and Technology Enhancement - CREATE V - Project 2

NCT07485712
Site status not listed — check the official record
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Project 2, Phase 2: Intelligent Adaptive System
Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
60 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
3
States / cities
Tallahassee, Florida • Champaign, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 22, 2026, 6:45 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma

NCT03334708
Status at this site: Not yet recruiting
View directory record Official record
Conditions
Pancreatic Cancer, Pancreatic Diseases, Pancreatitis, Pancreatic Cyst
Interventions
Blood Draw, Tumor Tissue Collection, Cyst Fluid
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
10
States / cities
Middletown, New Jersey • Montvale, New Jersey • Cold Spring Harbor, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 22, 2026, 6:45 AM EDT
Active, not recruiting Phase 1 Interventional

Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

NCT04013685
Site status not listed — check the official record
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Myelodysplastic Syndromes, Acute Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Chronic Myeloid Leukemia
Interventions
Orca-T
Biological
Lead sponsor
Orca Biosystems, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
21
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 22, 2026, 6:45 AM EDT
Recruiting Phase 1Phase 2 Interventional

Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

NCT06425926
Status at this site: Recruiting
View directory record Official record
Conditions
Melanoma Stage IV, Solid Tumor
Interventions
GIM-531, Anti-PD-1 monoclonal antibody
Drug
Lead sponsor
Georgiamune Inc
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
11
States / cities
Scottsdale, Arizona • Bakersfield, California • Fullerton, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 22, 2026, 6:45 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

NCT05869903
Site status not listed — check the official record
View directory record Official record
Conditions
Obesity, Overweight, Overweight or Obesity
Interventions
Orforglipron, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
3,127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
43
States / cities
Chandler, Arizona • Sun City West, Arizona • Concord, California + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 22, 2026, 6:45 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease

NCT03105102
Site status not listed — check the official record
View directory record Official record
Conditions
Crohn's Disease
Interventions
Placebo for Risankizumab SC, Risankizumab IV, Placebo for Risankizumab IV, Risankizumab SC, Risankizumab On-Body Injector (OBI)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
16 Years to 80 Years
Enrollment
1,336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
111
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 91 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 22, 2026, 6:45 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Calcium-Rich Food Versus Calcium Carbonate for Bone Health

NCT07763509
Site status not listed — check the official record
View directory record Official record
Conditions
Osteopenia, Osteoporosis, Bone Health in Perimenopausal Women, Menopause Related Conditions, Fracture Healing
Interventions
500 mg calcium from milk-derived minerals, Calcium Carbonate 500 MG
Other · Dietary Supplement
Lead sponsor
Cornell University
Other
Eligibility
40 Years to 90 Years · Female only
Enrollment
217 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 22, 2026, 6:45 AM EDT
Active, not recruiting Phase 3 Interventional

P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk

NCT06468033
Site status not listed — check the official record
View directory record Official record
Conditions
Primary Myelofibrosis, Myeloproliferative Neoplasm
Interventions
Ropeginterferon alfa-2b, Placebo
Biological · Other
Lead sponsor
PharmaEssentia
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
13
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Kansas City, Kansas + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 22, 2026, 6:45 AM EDT
Recruiting Phase 1 Interventional

Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

NCT05519449
Status at this site: Recruiting
View directory record Official record
Conditions
Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Castration Resistant Prostatic Cancer
Interventions
JANX007, Darolutamide
Biological · Drug
Lead sponsor
Janux Therapeutics
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
33
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 22, 2026, 6:45 AM EDT
Active, not recruiting No phase listed Observational

A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care

NCT06693531
Site status not listed — check the official record
View directory record Official record
Conditions
Eosinophilic Esophagitis (EoE)
Interventions
dupilumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
1 Year and older
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
54
States / cities
Phoenix, Arizona • Sun City, Arizona • Little Rock, Arkansas + 43 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 22, 2026, 6:45 AM EDT
Recruiting No phase listed Observational

Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry

NCT01915511
Status at this site: Recruiting
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
21 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2031
U.S. locations
47
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 22, 2026, 6:45 AM EDT

About this Weill Cornell Medicine institution page

What this page lists
ClinicalTrials.gov records that list Weill Cornell Medicine in New York, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.